Patents by Inventor Karla Henning
Karla Henning has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240141059Abstract: Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.Type: ApplicationFiled: August 30, 2023Publication date: May 2, 2024Inventors: Nils LONBERG, Alan J. KORMAN, Mark J. SELBY, Bryan C. BARNHART, Aaron P. YAMNIUK, Mohan SRINIVASAN, Karla A. HENNING, Michelle Minhua HAN, Ming LEI, Liang SCHWEIZER, Sandra V. HATCHER, Arvind RAJPAL
-
Publication number: 20230406939Abstract: The invention relates to dendritic cell-associated C-type lectin 2 (Dectin-2) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of providing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods of stimulating an antigen presenting cell.Type: ApplicationFiled: July 21, 2023Publication date: December 21, 2023Applicant: Bolt Biotherapeutics, Inc.Inventors: Shelley Erin ACKERMAN, David DORNAN, Karla A. HENNING, Justin A. KENKEL
-
Patent number: 11802162Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.Type: GrantFiled: October 25, 2019Date of Patent: October 31, 2023Assignee: Bristol-Myers Squibb CompanyInventors: Changyu Wang, Nils Lonberg, Alan J. Korman, Mark J. Selby, Mohan Srinivasan, Karla A. Henning, Michelle Minhua Han, Guodong Chen, Richard Huang, Indrani Chakraborty, Haichun Huang, Susan Wong, Huiming Li
-
Patent number: 11753474Abstract: The invention relates to dendritic cell-associated C-type lectin 2 (Dectin-2) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of providing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods of stimulating an antigen presenting cell.Type: GrantFiled: February 3, 2022Date of Patent: September 12, 2023Assignee: Bolt Biotherapeutics, Inc.Inventors: Shelley Erin Ackerman, David Dornan, Karla A. Henning, Justin A. Kenkel
-
Publication number: 20230086603Abstract: The invention relates to programmed death-ligand 1 (PD-L1) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of producing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods for enhancing or reducing or inhibiting an immune response in a mammal.Type: ApplicationFiled: January 21, 2021Publication date: March 23, 2023Applicant: BOLT BIOTHERAPEUTICS, INCInventors: Michael N. ALONSO, David DORNAN, Karla HENNING, Justin KENKEL, Marcin KOWANETZ, Heidi LEBLANC, William MALLET
-
Publication number: 20230069055Abstract: The invention relates to programmed death-ligand 1 (PD-L1) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of producing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods for enhancing or reducing or inhibiting an immune response in a mammal.Type: ApplicationFiled: January 21, 2021Publication date: March 2, 2023Applicant: BOLT BIOTHERAPEUTICS, INCInventors: Michael N. ALONSO, David DORNAN, Karla HENNING, Justin KENKEL, Marcin KOWANETZ, Heidi LEBLANC, William MALLET
-
Publication number: 20230051701Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.Type: ApplicationFiled: May 5, 2022Publication date: February 16, 2023Inventors: Nils Lonberg, Alan J. Korman, Bryan C. Barnhart, Aaron P. Yamniuk, Mohan Srinivasan, Karla A. Henning, Ming Lei, Emanuela Sega, Angela Goodenough, Maria N. Jure-Kunkel, Guodong Chen, John S. Sack, Richard Huang, Martin J. Corbett, Joseph E. Myers, JR., Liang Schweizer, Sandra V. Hatcher, Haichun Huang, Pingping Zhang
-
Publication number: 20230050665Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.Type: ApplicationFiled: June 30, 2021Publication date: February 16, 2023Inventors: Changyu WANG, Nils LONBERG, Alan J. KORMAN, Mark J. SELBY, Mohan SRINIVASAN, Karla HENNING, Michelle Minhua HAN, Guodong CHEN, Richard HUANG, Indrani CHAKRABORTY, Haichun HUANG, Susan WONG, Huiming LI
-
Publication number: 20220390463Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand (TL1A). The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.Type: ApplicationFiled: July 28, 2022Publication date: December 8, 2022Applicants: Pfizer Inc., Bristol-Myers Squibb CompanyInventors: Robert ARCH, Jun ZHANG, Michelle MADER, Tetsuya ISHINO, Joel BARD, William FINLAY, Orla CUNNINGHAM, Ciara REILLY, Peter BRAMS, Brigitte DEVAUX, Haichun HUANG, Karla HENNING
-
Patent number: 11474112Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand 1A(TL1A) The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.Type: GrantFiled: May 24, 2019Date of Patent: October 18, 2022Assignees: Pfizer Inc., Bristol-Myers Squibb CompanyInventors: Robert Arch, Jun Zhang, Michelle Mader, Tetsuya Ishino, Joel Bard, William Finlay, Orla Cunningham, Ciara Reilly, Peter Brams, Brigitte Devaux, Haichun Huang, Karla Henning
-
Patent number: 11408889Abstract: Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.Type: GrantFiled: May 8, 2020Date of Patent: August 9, 2022Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Xi-Tao Wang, Olufemi A. Adelakun, Anne C. Lewin, Alan J. Korman, Mark J. Selby, Changyu Wang, Haichun Huang, Karla A. Henning, Nils Lonberg, Mohan Srinivasan, Michelle Minhua Han, Guodong Chen, Richard Y. Huang, Indrani Chakraborty, Susan Chien-Szu Wong, Huiming Li
-
Publication number: 20220175921Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.Type: ApplicationFiled: November 19, 2021Publication date: June 9, 2022Inventors: Changyu WANG, Nils LONBERG, Alan J. KORMAN, Mark J. SELBY, Mohan SRINIVASAN, Karla A. HENNING, Michelle Minhua HAN, Guodong CHEN, Richard Y. HUANG, Indrani CHAKRABORTY, Haichun HUANG, Susan Chien-Szu WONG, Huiming LI, Bryan C. BARNHART, Aaron P. YAMNIUK, Ming LEI, Liang SCHWEIZER, Sandra V. HATCHER, Arvind RAJPAL
-
Patent number: 11352440Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.Type: GrantFiled: August 30, 2018Date of Patent: June 7, 2022Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Nils Lonberg, Alan J. Korman, Bryan C. Barnhart, Aaron P. Yamniuk, Mohan Srinivasan, Karla A. Henning, Ming Lei, Emanuela Sega, Angela Goodenough, Maria N. Jure-Kunkel, Guodong Chen, John S. Sack, Richard Y. Huang, Martin J. Corbett, Joseph E. Myers, Jr., Liang Schweizer, Sandra V. Hatcher, Haichun Huang, Pingping Zhang
-
Publication number: 20220153849Abstract: The invention relates to dendritic cell-associated C-type lectin 2 (Dectin-2) binding agents, nucleic acids comprising the inventive binding agents, vectors and cells comprising the inventive nucleic acids, and compositions thereof. The invention also relates to methods of providing the inventive binding agents, methods for treating a disease, disorder, or condition in a mammal, and methods of stimulating an antigen presenting cell.Type: ApplicationFiled: February 3, 2022Publication date: May 19, 2022Applicant: Bolt Biotherapeutics, Inc.Inventors: Shelley Erin Ackerman, David Dornan, Karla A. Henning, Justin A. Kenkel
-
Patent number: 11213586Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.Type: GrantFiled: November 17, 2016Date of Patent: January 4, 2022Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Changyu Wang, Nils Lonberg, Alan J. Korman, Mark J. Selby, Mohan Srinivasan, Karla A. Henning, Michelle Minhua Han, Guodong Chen, Richard Y. Huang, Indrani Chakraborty, Haichun Huang, Susan Chien-Szu Wong, Huiming Li, Bryan C. Barnhart, Aaron P. Yamniuk, Ming Lei, Liang Schweizer, Sandra V. Hatcher, Arvind Rajpal
-
Patent number: 11084881Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.Type: GrantFiled: September 23, 2019Date of Patent: August 10, 2021Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Changyu Wang, Nils Lonberg, Alan J. Korman, Mark J. Selby, Mohan Srinivasan, Karla Henning, Michelle Minhua Han, Guodong Chen, Richard Huang, Indrani Chakraborty, Haichun Huang, Susan Wong, Huiming Li
-
Publication number: 20210011022Abstract: Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.Type: ApplicationFiled: May 8, 2020Publication date: January 14, 2021Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Xi-Tao WANG, Olufemi A. ADELAKUN, Anne C. LEWIN, Alan J. KORMAN, Mark J. SELBY, Changyu WANG, Haichun HUANG, Karla A. HENNING, Nils LONBERG, Mohan SRINIVASAN, Michelle Minhua HAN, Guodong CHEN, Richard Y. HUANG, Indrani CHAKRABORTY, Susan Chien-Szu WONG, Huiming LI
-
Publication number: 20200299400Abstract: Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.Type: ApplicationFiled: May 24, 2018Publication date: September 24, 2020Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: Nils LONBERG, Alan J. KORMAN, Mark J. SELBY, Bryan C. BARNHART, Aaron P. YAMNIUK, Mohan SRINIVASAN, Karla A. HENNING, Michelle Minhua HAN, Ming LEI, Liang SCHWEIZER, Sandra V. HATCHER, Arvind RAJPAL
-
Publication number: 20200268901Abstract: Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.Type: ApplicationFiled: April 15, 2020Publication date: August 27, 2020Inventors: Nils LONBERG, Alan J. KORMAN, Mark J. SELBY, Bryan C. BARNHART, Aaron P. YAMNIUK, Mohan SRINIVASAN, Karla A. HENNING, Michelle Minhua HAN, Ming LEI, Liang SCHWEIZER, Sandra V. HATCHER, Arvind RAJPAL
-
Patent number: 10690674Abstract: Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.Type: GrantFiled: June 2, 2016Date of Patent: June 23, 2020Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Xi-Tao Wang, Olufemi A. Adelakun, Anne C. Lewin, Alan J. Korman, Mark J. Selby, Changyu Wang, Haichun Huang, Karla A. Henning, Nils Lonberg, Mohan Srinivasan, Michelle Minhua Han, Guodong Chen, Richard Y. Huang, Indrani Chakraborty, Susan Chien-Szu Wong, Huiming Li